Nitric oxide- and prostaglandin-mediated cardioprotection by bradykinin in myocardial ischema and reperfusion injury

Polish Journal of Pharmacology

Volumn 55, Issue 6, 2003, Pages 1021-1029

  Veeravalli, Krishna K ^a   Akula, Annapurna A ^a   Kota, Murali K ^a  

^a ANDHRA UNIVERSITY   (India)

Author keywords

Bradykinin; Cardioprotection; Ischemia; Nitric oxide; Reperfusion

Indexed keywords

ACETYLSALICYLIC ACID; AMINOPEPTIDASE P; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE; ENALAPRIL; ICATIBANT; LIPID PEROXIDE; LISINOPRIL; MALONALDEHYDE; MERCAPTOETHANOL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTAGLANDIN; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CORONARY REPERFUSION; DRUG INHIBITION; ELECTROCARDIOGRAPHY; ENZYME INHIBITION; FEMALE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VIVO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; MEASUREMENT; NONHUMAN; RAT; REPERFUSION INJURY; SPECTROPHOTOMETRY;

ANIMALS; BRADYKININ; ELECTROCARDIOGRAPHY; FEMALE; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NITRIC OXIDE; PROSTAGLANDINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, BRADYKININ;

EID: 1642503089     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Akula A., Veeravalli K.K., Potha Raju S., Kota M.K.: Studies on the signal cascade mechanism mediating the cardioprotective actions of bradykinin. Pharmazie, 2002, 57, 332-336.
2. Alabaster V.A., Bakhle Y.S.: The bradykininase activities of extracts of dog lung. Brit. J. Pharmacol., 1973, 47, 799-807.
3. Ambrosio G., Chiariello M.: Myocardial reperfusion injury: mechanisms and management: a review. Amer. J. Med., 1985, 91, 86S.
4. Annapurna A., Krishna Kumar V.: Effect of inhibition of angiotensin converting enzyme by ramipril and aminopeptidase P by 2-mercaptoethanol in rats with experimental myocardial infarction. Indian J. Pharmacol., 2001, 33, 72-76.
5. Annapurna A., Rajendra Babu M., Kesav Reddy Y.S.C., Krishna Kumar V.: Cardioprotective effects of acutely administered ramipril and losartan on myocardial infarct size in cholesterol-fed and salt-fed rats. Indian J. Pharmacol., 2001, 33, 437-441.
6. Annapurna A., Rajendra Babu M., Ranganayakulu D.: Cardioprotective actions of enalapril and lisinopril on ischemia-reperfusion induced myocardial infarction in normal and salt loaded rats. Indian J. Pharmacol., 2000, 32, 202-205.
7. Annapurna A., Sreenivas G., Krishna Kumar V.: Possible role of nitric oxide in the cardioprotective actions of enalapril and lisinopril in rats. Indian J. Pharm. Sci., 2002, 64, 151-154.
8. Bhoola K.D., Figueroa C.D., Worthy K.: Bioregulation of kinins: kallikreins, kininogens and kininases. Pharmacol. Rev., 1992, 44, 1-80.
9. Bjornstad-Ostensen A., Holte H.R., Berg T.: Amplification of kinin-induced hypotension by nitric oxide synthesis in spontaneously hypertensive rats. Hypertension, 1997, 29, 53-57.
10. Bolli R.: Mechanism of myocardial "stunning". Circulation, 1990, 82, 723-738.
11. Chopra K., Reddy D.S., Singh M.: Cardioprotective actions of ACE inhibitors on ischemic myocardium: an overview. Indian Drugs, 1995, 32, 464-470.
12. Dendorfer A., Wolfrum S., Wellhoner P., Korsman K., Dominiak P.: Intravascular and interstitial degradation of bradykinin in isolated perfused rat heart. Brit. J. Pharmacol., 1997, 122, 1179-1187.
13. + is an endothelium-derived hyperpolarizing factor in rat arteries. Nature, 1998, 396, 269-272.
14. Ehring T., Baumgart D., Krajcar M., Hunmmelgen M., Kompa S., Heusch G.: Attenuation of myocardial stunning by the ACE inhibitor ramiprilat through a signal cascade of bradykinin and prostaglandins but not nitric oxide. Circulation, 1994, 90, 1368-1385.
15. Erdos E.G.: Some old and some new ideas on kinin metabolism. J. Cardiovasc. Pharmacol., 1990, 15, Suppl. 6, S20-S24.
16. Erdos E.G.: Inhibitors of some recently characterized kinin metabolizing enzymes: a brief overview. Agent. Action., 1992, 38, Suppl, 454-461.
17. Ersahin C., Simmons W.H.: Inhibition of both aminopeptidase P and angiotensin-converting enzyme prevents bradykinin degradation in the rat coronary circulation. J. Cardiovasc. Pharmacol., 1997, 30, 96-101.
18. 1 attenuates post ischemic contractile dysfunction after brief coronary occlusion and reperfusion. Amer. Heart J., 1989, 118, 17-24.
19. Farber N.E., Gross G.J.: Prostaglandin redirection by thromboxane synthase inhibition: attenuation of myocardial stunning in canine heart. Circulation, 1990, 81, Suppl. I, I369-I380.
20. Farber N.E., Pieper G.M., Thomas J.P., Gross G.J.: Beneficial effects of iloprost in the stunned canine myocardium. Circ. Res., 1988, 62, 204-215.
21. Fishbein M.C., Meerbaum S., Rit J.: Early phase acute myocardial infarct size quantification. Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Amer. Heart J., 1981, 101, 593-600.
22. Fisslthaler B., Popp R., Kiss L., Potente M., Harder D.R., Fleming I., Busse R.: Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature, 1999, 401, 493-497.
23. G-nitro-L-arginine methyl ester. Brit. J. Pharmacol., 1990, 101, 632-639.
24. Gelvan D., Saltman P., Powell S.R.: Cardiac reperfusion damage prevented by a nitric oxide free radical. Proc. Nat. Acad. Sci. USA, 1991, 88, 4680-4684.
25. Gonzalez W., Beslot F., Laboulandine I., Zaluski M.C.F., Roques B.P., Michel J.B.: Inhibition of both ACE and NEP by S21402 (RB105) in rats with experimental myocardial infarction. J. Pharmacol. Exp. Ther., 1996, 278, 573-581.
26. Hartman J.C., Hullinger T.G., Wall T.M., Shebuski R.J.: Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur. J. Pharmacol., 1993, 234, 229-236.
27. Hartman J.C., Wall T.M., Hullinger T.G., Shebuski R.J.: Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J. Cardiovasc. Pharmacol., 1993, 21, 996-1003.
28. Heusch G., Rose J., Ehring T.: Cardioprotection by ACE inhibitors in myocardial ischemia-reperfusion. The importance of bradykinin. Drugs, 1997, 54, 31-41.
29. Hoffman M.J., Greenfield L.J., Sugerman H.J., Tatum J.L.: Unsuspected right ventricular dysfunction in shock and sepsis. Ann. Surg., 1983, 198, 307-319.
30. Ishida. H., Scicli A.G., Carretero O.A.: Contributions of various rat plasma peptidases to kinin hydrolysis. J. Pharmacol. Exp. Ther., 1989, 251, 817-820.
31. Ishida H., Scicli A.G., Carretero O.A.: Role of angiotensin converting enzyme and other peptidases in in vivo metabolism of kinins. Hypertension, 1989, 14, 322-327.
32. Johnson G., Tsao P.B.S., Lefer A.M.: Synergism between superoxide dismutase and sodium nitrate in cardioprotection following ischemia and reperfusion. Amer. Heart. J., 1990, 119, 530-538.
33. Juggi J.S., Koenig Berard E., Van Glist W.H.: Cardio-protection by ACE inhibitors. Can. J. Cardiol., 1993, 9, 336-352.
34. Kaplan A.P., Joseph K., Shibayama Y., Reddigari S., Ghebrehiwet B., Silverberg M.: The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv. Immunol., 1997, 66, 225-272.
35. Kilgore K.S., Lucchesi B.R.: Effect of hypoxia and re-oxygenation on the isolated rabbit heart determined by monoclonal antimyosin antibody uptake. Cardiovasc. Res., 1993, 27, 1260-1267.
36. Langlois P.F., Gawryl M.S.: Detection of the terminal complement complex in patient plasma following acute myocardial infarction. Atherosclerosis, 1988, 77, 95-105.
37. Linz W., Scholkens B.A.: Influence of local converting enzyme inhibition on angiotensin and bradykinin effects in ischemic rat hearts. J. Cardiovasc. Pharmacol., 1987, 10, Suppl. 7, S75-S82.
38. Linz W., Scholkens B.A., Han Y.F.: Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts. J. Cardiovasc. Pharmacol., 1986, 8, Suppl. 10, S91-S99.
39. Linz W., Wiemer G., Scholkens B.A.: ACE-inhibition induces no inflammation in cultured bovine endothelial cells and protects isolated ischemic rat hearts. J. Mol. Cell. Cardiol., 1992, 24, 909-917.
40. Liu Y.H., Yang X.P., Sharov V.G., Sigmon D.H., Sabbah H.N., Carretero O.A.: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension, 1996, 27, 7-13.
41. Marcus M.L., Koyanagi S., Harrison D.G., Doty D.B., Hiratzka L.F., Eastham C.L.: Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Amer. J. Med., 1983, 75, 62-66.
42. Meijler F.L.: Contribution of the risk factor concept to patient care in coronary heart disease. J. Amer. Coll. Cardiol., 1983, 1, 13-19.
43. Meng H., Pierce G.N.: Protective effect of 5-(N,N-dimethyl)-amiloride on ischemia reperfusion injury in hearts. Amer. J. Physiol., 1990, 27, H1615-H1619.
44. Miura T.: Adenosine and bradykinin: are they independent triggers of preconditioning? Basic Res. Cardiol., 1996, 91, 20-22.
45. Mombouli J.V., Illiano S., Nagao T., Scolt-Burden T., Vanhoutte P.M.: Potentiation of endothelium-dependent relaxations to bradykinin by angiotensin I converting enzyme inhibitors in canine coronary arteries involves both endothelium-derived relaxing and hyperpolarizing factors. Circ. Res., 1992, 71, 137-144.
46. Mombouli J.V., Vanhoutte P.M.: Endothelium-derived hyperpolarizing factors: updating the unknown. Trends Pharmacol. Sci., 1997, 18, 252-256.
47. Noda K., Sasaguri M., Ideishi M., Ikeda M., Arakawa K.: Role of locally formed angiotensin II and bradykinin in the reduction of myocardial infarct size in dogs. Cardiovasc. Res., 1993, 27, 334-340.
48. Ohkawa H., Ohishi N., Yagi K.: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95, 351-358.
49. Orawski A.T., Surz J.P., Simmons W.H.: Metabolism of bradykinin by multiple coexisting membrane-bound peptidases in lung: techniques for investigating the role of each peptidase using specific inhibitors. Adv. Exp. Med. Biol., 1989, 247B, 355-364.
50. Palmer R.M.J., Rees D.P., Ashton D.S., Moncada S.: L-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun., 1988, 153, 1251-1256.
51. Prechel M.M., Orawski A.T., Maggiora L.L., Simmons W.H.: Effect of a new aminopeptidase P inhibitor, apstatin on bradykinin degradation in the rat lung. J. Pharmacol. Exp. Ther., 1995, 275, 1136-1142.
52. Przyklenk K., Kloner R.A.: Acute effects of hydralazine and enalapril on contractile function of postischemic 'stunned' myocardium. Amer. J. Cardiol., 1987, 60, 934-936.
53. Przyklenk K., Kloner R.A.: Angiotensin converting enzyme inhibitors improve contractile function of stunned myocardium by direct mechanisms of action. Amer. Heart J., 1991, 121, 1319-1330.
54. Przyklenk K., Kloner R.A.: Cardioprotection by ACE inhibitors in acute myocardial ischemia and infarction. Basic Res. Cardiol., 1993, 88, 139-154.
55. Rees D.D., Palmer R.M., Schulz R., Hodson H.F., Moncada S.: Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Brit. J. Pharmacol., 1990, 101, 746-752.
56. Remme W.J.: Bradykinin-mediated cardiovascular protective actions of ACE inhibitors. A new dimension in anti-ischemic therapy? Drugs, 1997, 54, Suppl. 5, 59-70.
57. Romson J.L., Hook B.G., Kunkel S.S., Abrams G.D., Schork M.A., Lucchesi B.R.: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation, 1983, 67, 1016-1023.
58. Scholkens B.A.: Kinins in the cardiovascular system. Immunopharmacology, 1996, 30, 209-216.
59. Scholkens B.A., Linz W., Koenig W.: Effects of the angiotensin converting enzyme inhibitor, ramipril, in isolated ischaemic rat heart are abolished by a bradykinin antagonist. J. Hypertension, 1988, 6, S25-S28.
60. 1 inhibition of ischemia-induced neutrophil activation. Naunyn-Schmied. Arch. Pharmacol., 1988, 338, 268-274.
61. Siragy H.M.: Evidence that intrarenal bradykinin plays a role in regulation of renal function. Amer. J. Physiol., 1993, 265, E648-E654.
62. Skidgel R.A.: Bradykinin-degrading enzymes: structure, function, distribution and potential roles in cardiovascular pharmacology. J. Cardiovasc. Pharmacol., 1992, 20, Suppl. 9, S4-S9.
63. Van Glist W.H., de Groeff P.A., Wesseling H., de Langen C.D.J.: Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril and HOE 498. J. Cardiovasc. Pharmacol., 1986, 8, 722-728.
64. Westlin W., Mullane K.: Does captopril attenuate reperfusion induced myocardial dysfunction by scavenging free radicals? Circulation, 1988, 77, Suppl. 1, I30-I39.
65. Wiemer G., Scholkens B.A., Becker R.H.A., Busse R.: Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium derived bradykinin. Hypertension, 1991, 18, 558-563.
66. Williamson J.R.: Contribution of tissue acidosis to ischemic injury in the perfused rat heart. Circulation, 1976, 53, 13-14.
67. Yagi K.: A simple fluorometric assay for lipoperoxide in blood plasma. Biochem. Med., 1976, 15, 212-216.
68. Young J.B.: Reduction of ischemic events with ACE inhibitors: lessons and controversy emerging from recent clinical trials. Cardiovasc. Drug. Therapy, 1995, 9, 89-102.
69. Zughaib M.E., Sun J.Z., Bolli R.: Effect of angiotensin converting enzyme inhibitors on myocardial ischemia-reperfusion: an overview. Basic Res. Cardiol., 1993, 88, 155-167.